Catalyst Wire Dossier Catalyst Wire Dossier

Leuprolide Acetate Injectable Suspension 22.5 mg

Leuprolide acetate · Oakwood Laboratories, LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Leuprolide Acetate Injectable Suspension 22.5 mg, covering 2010-09-08 to 2010-09-08. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Study of Leuprolide Acetate for Injectable Suspension 22.5 MG in the Treatment of Prostate Cancer [Phase 3]

See pricing